Answers are grounded in this paper and cite their sources.
Reported pertussis cases in China surged from 6,658 in 2015 to 476,690 in 2024 (a 71.6-fold increase), with a sharp decline during COVID-19 (2020) and an explosive resurgence in 2023–2024 despite sustained DTaP3 coverage above 95%; the transmission dynamics behind this resurgence remain incompletely quantified. In this national surveillance-based modeling study, we fitted a seasonally forced SEIARV compartmental model with waning immunity to all reported monthly pertussis cases of all ages in China (January 2015 to December 2024), reconstructed the time-varying effective reproduction number Re, and forecast 2025–2027 incidence under four transmission scenarios using 500-member stochastic ensembles. Re ranged from 0.88 (2020) to 1.37 (2023), with pre-pandemic values of 0.98–1.07 and annual fitting errors below 5% (in-sample RMSE 2.6%). A counterfactual analysis estimates that COVID-19 non-pharmaceutical interventions increased the effective susceptible population by approximately 14% by early 2023, an upper-bound estimate that cannot be fully separated from pandemic-era vaccine hesitancy. The fitted baseline transmission rate β0 rose from 8.96 month−1 (2020) to a decade-high 13.82 month−1 (2023; +29% vs. the pre-COVID-19 mean), and waning acellular-vaccine protection further amplified transmission (sensitivity index of Re to the waning rate: +0.79); their separate contributions cannot be formally decomposed in a homogeneous national model. Forecasts indicate that strengthened control could reduce annual cases to near zero by 2027 (median 0; 95% prediction interval 0–155), whereas continued waning or a return to historical-maximum transmission would sustain millions of cases (medians 9.3 and 10.8 million; outbreak probabilities 97–100%).
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: